Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07400757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Feb 20, 2026 to Feb 24, 2026
    • Site details revised
    v3
  2. Notable Primary endpoints revised (4)
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description shortened, about 1 word
    v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are: * Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis? * Does vitamin D supplementation change disease activity in patients with active thyroid eye disease? * Does combined treatment with statin and vitamin D produce different effects compared with either treatment alone or standard care? * What adverse events occur during treatment? Researchers will compare four groups: standard care alone, statin therapy plus standard care, vitamin D supplementation plus standard care, and combined statin and vitamin D therapy plus standard care. Participants will: * Be randomly assigned to one of four treatment groups * Receive the assigned treatment for 24 weeks * Attend clinic visits for clinical assessments and blood tests at baseline and at 24 weeks * Be followed through medical record review for up to three years after completion of the intervention
Trial Details
NCT Number NCT07400757
Lead Sponsor Taipei Veterans General Hospital, Taiwan
Conditions
(from sponsor)
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Related terms Autoimmune Diseases, Graves Ophthalmopathy, Inflammation
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov